You are here

Prices & Quotes - UK Markets - Benchmark Holdings (BMK)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Up 54.00p
Change Today:
1.00p
Market Cap:
£380.04m
Sector:
Pharmaceuticals & Biotechnology

Revenue and earnings buoyant at Benchmark

By Josh White

Date: Tuesday 24 Aug 2021

LONDON (ShareCast) - (Sharecast News) - Benchmark reported a 17% improvement in revenues year-on-year in its third quarter on Tuesday to £28.3m, or 25% at constant exchange rates, with "strong" performance across all of its business areas.
The AIM-traded genetics and aquaculture company said revenues in genetics were 21% higher than the prior year in the three months ended 30 June, driven by higher sales of salmon eggs.

In advanced nutrition, revenues were 15% firmer, which the board put down to growth across all of its product lines, and continuing good performance.

Finally, health revenues were 20% above the third quarter of 2020, benefiting from higher Salmosan sales.

Adjusted EBITDA "more than doubled" to £4.4m, as a result of higher revenues, operational improvements and continuous cost control.

Looking at the year-to-date, group revenues were 9% higher than the prior year, and adjusted EBITDA was 26% firmer, from continuing operations.

Benchmark said its liquidity totalled £51m of cash and available facilities as at 23 August.

On the operational front, the firm launched 'Ectosan Vet', formerly BMK08, and 'CleanTreat' after the quarter ended, with the first sea lice treatments delivered successfully.

Also after the period ended, the group received marketing authorisation in Norway for Ectosan Vetm and the maximum residue limit (MRL) was adopted into the agreement of the European Economic Area, completing the regulatory steps for commercialisation.

The first treatments were successfully delivered in August, with Ectosan Vet the first new sea lice medicine to come to market in more than a decade.

Good commercial and operational momentum in advanced nutrition was continuing with "strong growth" year-on-year, while expansion projects for salmon and shrimp genetics in Iceland, Fellsmere and Chile were progressing according to plan.

The firm was continuing to win new contracts for future delivery in the emerging land-based salmon segment, the board said.

Looking at the wider market environment, Benchmark said the reopening of the hospitality sector was creating a positive outlook, while conditions in the salmon industry were "positive", with a recovery in prices after a drop related to Covid-19, and demand growth still exceeding global supply.

The shrimp market was recovering with the potential to bounce back to pre-Covid-19 levels, despite continued hardships due to the pandemic in certain markets, while the seabass and seabream market had "substantially" recovered.

Benchmark said it was trading in line with market expectations for the full year, with "good" revenue visibility for the rest of the year.

Looking towards the 2022 financial year, a consistent performance was expected to continue in genetics and advanced nutrition, while the board said the health division would start to benefit from the Ectosan Vet and CleanTreat revenue streams.

"We are very pleased with the results and progress in the third quarter, and the subsequent period," said chief executive officer Trond Williksen.

"Our three business areas performed strongly, and we achieved a major strategic milestone with the successful commercial launch of Ectosan® Vet and CleanTreat.

"We now have the basis to have three profitable business areas moving the group closer to overall profitability."

Williksen said there was "good momentum" in the business following the streamlining exercise conducted in 2020, and the adoption of a new commercial focus.

"Our end markets are gradually recovering from the impact of Covid-19, creating a positive environment for our business.

"All this provides confidence in our ability to deliver full year results in line with market expectations as well as progress in future years."

At 1014 BST, shares in Benchmark Holdings were up 4% at 62.4p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

BMK Market Data

Currency UK Pounds
Price 54.00p
Change Today 1.00p
52 Week High 65.00p
52 Week Low 52.00p
Volume 175,293
Shares Issued 703.79m
Market Cap £380.04m
Beta 0.02

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. half sector star
  5. empty sector
Price Trend
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Price Chg 6m
market
  1. full market star
  2. full market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. empty sector
  5. empty sector
P/E
Not Available
PEG
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

BMK Dividends

No dividends found

Trades for 26-Jan-2022

Time Volume / Share Price
10:24 20,000 @ 54.00p
08:43 100,000 @ 52.00p
09:35 7,500 @ 54.00p
09:34 47,612 @ 53.74p
09:18 157 @ 52.04p

BMK Key Personnel

CFO Septima Maguire
CEO Trond Williksen